NCT02470026

Noradrenergic Activity, Cognition and Major Depressive Disorder

Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 131 (actual)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study investigates influences of nordadrenergic activity on cognition in patients with major depression regarding influences of early life stress.

Detailed description

Stress plays a major role in the development and maintenance of major depression disorder. Indeed, various studies demonstrated maladaptive changes in physiological stress regulation systems of depressive patients, i.e. in the hypothalamus-pituitary-adrenal axis and the locus coeruleus-noradrenergic system. On a central level, changes of the locus coeruleus-noradrenergic system have been demonstrated.This seems to be the case especially in depressive patients with early life traumata. Comparable to the hypothalamus-pituitary-adrenal axis, the locus coeruleus-noradrenergic system influences not only the physiological stress response, but has also central influence with effects on cognitive functions. Indeed, noradrenergic effects on cognitive functions such as attention, learning and memory have been demonstrated in healthy individuals. Even though deficits in cognitive domains are core symptoms of major depression, the relationship of the noradrenergic system and cognitive processes has rarely been investigated so far. In this project, the investigators will examine noradrenergic influences via administration of the alpha2-receptor blocker yohimbine on cognitive and emotionally relevant processes in depressive patients and controls. Additionally, the investigators will examine the influence of early life traumata on these relationships. Thus, the investigators will examine participants with and without major depression and with and without early life stress. Results of this study will improve the understanding of cognitive dysfunctions associated with the noradrenergic system in patients with major depression.

Conditions

• Major Depressive Disorder
• Early Life Trauma

Interventions

Type	Name	Description
DRUG	yohimbine	single low dose treatment
DRUG	placebo	single control treatment

Timeline

• Start date: 2014-06-01
• Primary completion: 2017-11-01
• Completion: 2018-10-01
• First posted: 2015-06-12
• Last updated: 2019-05-23

Locations

1 site across 1 country: Germany